Press release – No. 14 / 2025 Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Copenhagen, Denmark, September 24, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Rachel James-Owens as Vice President, Corporate Communications & Media Relations. Rachel brings over 20 years of global pharmaceutical experie ...

Company Overview - Zealand Pharma A/S is a biotechnology company focused on the discovery and development of innovative peptide-based medicines [3][4] - The company has advanced more than 10 drug candidates into clinical development, with two reaching the market and three in late-stage development [3] - Zealand Pharma has development partnerships with several pharmaceutical companies and commercial partnerships for its marketed products [3] Share Capital Information - As of June 30, 2025, Zealand Pharma has a total of 71,343,804 shares, with a nominal value of DKK 1 each [3] - The total share capital and number of voting rights are both reported as 71,343,804 [3][2] - The share capital increase was due to the exercise of employee warrants, as announced in Company Announcement No. 14 / 2025 dated June 6, 2025 [2]